Mitrovic, Mirjana (54972086700)Mirjana (54972086700)MitrovicPantic, Nikola (57221630977)Nikola (57221630977)PanticSabljic, Nikica (57221634280)Nikica (57221634280)SabljicVucic, Miodrag (9840397700)Miodrag (9840397700)VucicBukumiric, Zoran (36600111200)Zoran (36600111200)BukumiricVirijevic, Marijana (36969618100)Marijana (36969618100)VirijevicPravdic, Zlatko (57221636770)Zlatko (57221636770)PravdicRajic, Jovan (57435044600)Jovan (57435044600)RajicTodorovic-Balint, Milena (55773026600)Milena (55773026600)Todorovic-BalintVidovic, Ana (6701313789)Ana (6701313789)VidovicSuvajdzic-Vukovic, Nada (36446767400)Nada (36446767400)Suvajdzic-Vukovic2025-07-022025-07-022021https://doi.org/10.1080/10428194.2021.1964026https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112401585&doi=10.1080%2f10428194.2021.1964026&partnerID=40&md5=f10104b2c76d8e0d924851bafb1ec6fchttps://remedy.med.bg.ac.rs/handle/123456789/12399Patients with acute leukemia (AL) have a high mortality rate from coronavirus disease 2019 (COVID-19). However, studies including patients with AL and COVID-19 are few. Fifty-one patients with AL and COVID-19 were included in our study. The mortality rate was 17/51 (29.4%). In all cases, death was associated with COVID-19 pneumonia. The major driver of outcome was the disease status (worse outcome was observed in newly diagnosed (OR, 6.00; 95% CI, 1.133–15.188) and patients with bone marrow aplasia (OR 4.148 [95% CI 1.133–15.188])). Higher mortality rate was associated with lower platelet count, prolonged PT, higher ISTH DIC score, CRP and LDH. Moreover, careful risk-benefit assessment regarding the continuation of anticancer therapy is required in patients receiving nonintensive and supportive therapy. Considering the high frequency of intrahospital viral transmission (50.98%), isolation of AL patients in single rooms, and permanent symptom monitoring and testing should be prioritized. © 2021 Informa UK Limited, trading as Taylor & Francis Group.